Purpose: EGFR classical mutations respond well to EGFR tyrosine kinase inhibitors. However, it is uncertain whether currently available EGFR-TKIs are effective against rare EGFR mutations and compound mutations. Herein, the effectiveness of almonertinib and alflutinib, the third-generation tyrosine kinase inhibitors developed in China, on rare EGFR S768I mutations and compound mutations is identified.
Methods: In this study, using CRISPR method, four EGFR S768I mutation cell lines were constructed, and the sensitivity of EGFR to almonertinib and alflutinib was tested, with positive controls being the 1st (gefitinib), 2nd (afatinib), and 3rd (osimertinib) generation drugs.
Results: The present results indicate that almonertinib and alflutinib can effectively inhibit cell viability and proliferation in rare EGFR S768I mutations through the ERK or AKT pathways in a time-dependent manner, by blocking the cell cycle and inhibiting apoptosis.
Conclusions: These findings suggest that almonertinib and alflutinib may be potential therapeutic options for non-small cell lung cancer patients with the EGFR S768I mutation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12094-024-03494-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms-An In Vitro Study.
Biomedicines
June 2024
Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama 589-8511, Japan.
Article Synopsis
- - The study investigates the inevitable emergence of acquired resistance to EGFR-TKIs in lung cancer, focusing on secondary mutations like T790M and C797S that contribute to resistance against first/second-generation (1/2G) and third-generation (3G) inhibitors, respectively.
- - Researchers assessed the effectiveness of a novel fourth-generation EGFR-TKI, BI4020, against lung cancer models that had developed resistance after osimertinib treatment, revealing its efficacy only against certain mutations but not against L718Q-positive cells.
- - The findings indicate that while erlotinib remained effective against all tested resistant cells, BI4020 resistance did not involve secondary mutations but included gene amplification and epithelial-to-mes
Almonertinib and alflutinib show novel inhibition on rare EGFR S768I mutant cells.
Clin Transl Oncol
December 2024
Translational Medicine Center, Huaihe Hospital of Henan University, Henan University, No. 115, Ximen Avenue, Kaifeng, 475000, China.
Purpose: EGFR classical mutations respond well to EGFR tyrosine kinase inhibitors. However, it is uncertain whether currently available EGFR-TKIs are effective against rare EGFR mutations and compound mutations. Herein, the effectiveness of almonertinib and alflutinib, the third-generation tyrosine kinase inhibitors developed in China, on rare EGFR S768I mutations and compound mutations is identified.
View Article and Find Full Text PDFSpotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, "uncommon-G719X, S768I, L861Q") Among the Third-Generation EGFR TKIs?
Lung Cancer (Auckl)
October 2022
University of California Irvine School of Medicine, Department of Medicine, Department of Medicine, Orange, CA, USA.
Osimertinib, a third-generation (3G) epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is now considered the standard of care for the first-line (1L) treatment of advanced + NSCLC due to statistically significant improved progression-free survival (PFS) and overall survival (OS) compared with first-generation (1G) treatment from the FLAURA trial. Recently two other 3G EGFR TKIs (aumolertinib and furmonertinib) have been approved in China for treatment of T790M+ NSCLC. Randomized Phase 3 trials of these two 3G EGFR TKIs have also demonstrated PFS over gefitinib respectively.
View Article and Find Full Text PDFEGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research.
Pharmacol Res
May 2021
Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, 210009 Nanjing, China. Electronic address:
With the development of precision medicine, molecular targeted therapy has been widely used in the field of cancer, especially in non-small-cell lung cancer (NSCLC). Epidermal growth factor receptor (EGFR) is a well-recognized and effective target for NSCLC therapies, targeted EGFR therapy with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) has achieved ideal clinical efficacy in recent years. Unfortunately, resistance to EGFR-TKIs inevitably occurs due to various mechanisms after a period of therapy.
View Article and Find Full Text PDFBeyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC.
J Thorac Oncol
May 2021
Division of Hematology/Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California. Electronic address:
Article Synopsis
- Osimertinib is the current standard treatment for advanced EGFR+ NSCLC, with almonertinib approved in China in March 2020 for a specific mutation (EGFR T790M).
- The review highlights various third-generation EGFR TKIs under late-stage clinical development, discussing their trial results, study designs, and chemical structures when available.
- It also summarizes past clinical trial results of other third-generation TKIs and details ongoing combination trials that could lead to new standard treatments for advanced EGFR+ NSCLC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!